Edvince is a groundbreaking brand that develops revolutionary treatments for stroke, aimed at improving the lives of patients and benefiting society as a whole. The brand's research is based on pioneering discoveries in the field of cerebral circulation and receptor regulation. Despite the extensive research and clinical trials in stroke treatment, there is currently a lack of effective treatments and promising drug candidates.

Edvince offers a fresh perspective and a new approach to address this urgent need. Founded by Professor Lars Edvinsson, a leading expert in cerebral circulation, the brand's drug discovery and development is rooted in his extensive and fundamental research on stroke, migraines, and vascular innervation. Edvince is currently conducting a clinical trial for their innovative lead drug, EDV2209, specifically designed to treat brain ischemia associated with severe subarachnoid hemorrhage.

This orphan drug helps keep the blood vessels in the brain open, allowing for the delivery of oxygen and nutrients to prevent brain damage. With a robust pipeline, Edvince has the opportunity to expand into other stroke indications, including global ischemic stroke, which has a high market potential. The brand's team consists of accomplished professionals committed to advancing their therapeutic area expertise.

Edvince also collaborates with Rigshospitalet, an engaged partner that supports their clinical trial. Edvince's dedication to revolutionizing stroke treatment and its partnerships demonstrate their commitment to making a significant impact in the field of healthcare. With their pioneering research and disruptive approach, Edvince is poised to bring about a paradigm shift in the treatment of stroke.

Visit their website to learn more about their innovative solutions and the future of stroke treatment